ClinicalTrials.gg
Status unknownNCT04826107Updated Apr 1, 2021

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

A Phase 2 interventional study of DP303c treatment and DP303c treatment(second-line of HER2-positive) in Gastric Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.

Read the detailed description

This is an open-label, multicenter, phase II study of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer with two parts. In part 1, patients will be treated with DP303c injection at three dose levels (2.0 mg/kg,2.5 mg/kg or 3.0 mg/kg) every 3 weeks to determine the recommended dose . Once the recommended dose has been established in part 1, patients will be enrolled into 4 cohorts in part 2.

02

Conditions studied

  • Gastric Cancer

Browse trials for

03

In context

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

This study's planned enrollment of 196 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in this study and sign the form.
  2. Age ≥18 and ≤75 years, regardless of gender.
  3. Unresectable locally advanced, recurrent or gastric cancer (including gastric-esophageal junction adenocarcinoma) confirmed by histopathology and/or cytology; patients have received at least the platinum or taxane based treatment (Patients who have progressed or recurred during /adjuvant therapy or within 6 months after completion of treatment can participate. In this case, neoadjuvant/adjuvant therapy can be counted as one previous (1st-line) therapy); for each cohort in part 2, -positive patients must also include trastuzumab or trastuzumab analog in the previous 1st-line therapy.

    Part 1 Progression on or after ≥ 1st-line treatment, HER2 positive. Part 2 Cohort A: Progression on or after 1st-line treatment, HER2 positive; Cohort B: Progression on or after ≥ 2nd-line of treatment, HER2 positive; Cohort C: Progression on or after ≥ 1st-line treatment, low expression of HER2; Cohort D: Progression on or after ≥ 1st-line treatment, HER2 low expression or HER2 positive.

    HER2 positive expression is defined as IHC 3+ or IHC 2+ with ISH test positive; HER2 low expression is defined as IHC 1+ or IHC 2+ with ISH test negative.

  4. (ECOG) score of 0-1, and ≥ 3 months.
  5. The function of major organs must meet the following criteria within 7 days before enrollment (Have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 14 days before the first dose of study drug):

    (ANC) ≥1.5×109 /L, ≥100×109 /L; ≥90 g/L or ≥5.6 mmol/L; (INR) or prothrombin time (PT) ≤1.5×; Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN; rate ≥30 mL/min (Calculated by Cockcroft-Gualt formula); Total ≤1.5×ULN, or ≤3×ULN for patients with Gilbert's syndrome or liver metastasis; (AST) and Alanine aminotransferase (ALT) ≤2.5×ULN, or ≤5×ULN for patient.

  6. At least one at baseline per v1.1.
  7. Women of childbearing age must have a negative pregnancy test prior to study entry.
  8. Female and male patient of childbearing age must agree to take adequate measures during the entire study period and through at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to 5.0), except for alopecia, pigmentation and other toxicity judged no safety risk by the investigator.
  3. Patients who have previously received trastuzumab or trastuzumab analogues and have related toxicity, resulting in permanent discontinuation.
  4. Patients with history of allergy to any components (trastuzumab analogues, MMAE, sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sucrose, etc.) of DP303c.
  5. Patients with brain or pia mater ; except for patients with central nervous system (CNS) metastases in the following conditions: untreated but asymptomatic, or progression-free status in imaging evidence for at least 4 weeks after treatment and not requiring hormone therapy for at least 4 weeks.
  6. Patients with pleural effusions or ascites that are difficult to control (the frequency of percutaneous drainage is more than once a week, or continuous drainage daily volume is ≥500 mL).
  7. The patient had acute and chronic gastrointestinal bleeding with hematemesis or melena within 4 weeks before the first administration of study drug (except for patients with only the fecal occult blood test positive, but without visible bleeding such as melena or hematemesis).
  8. Patients with gastrointestinal obstruction.
  9. Patients with dyspnea at rest induced by complications of advanced malignant tumors or need for continuous oxygen therapy.
  10. History of any other malignant tumors within five years (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, cervical cancer in situ and other malignant tumors that have been radically removed and have not recurred).
  11. History of (non-infectious) interstitial pneumonia/pulmonary disease that requires treatment, or current interstitial pneumonia/pulmonary disease, or suspected interstitial pneumonia/pulmonary disease that cannot be excluded by imaging examination; except for patients with radiation pneumonitis without clinical symptoms after 3 months of radiotherapy.
  12. Patients who currently have corneal diseases that require medication or surgical intervention, or have a history of serious corneal diseases, or are unwilling to stop wearing contact lenses during the study.
  13. History of congestive heart failure, unstable angina pectoris, arrhythmia.

    Patients with the following cardiac function defects at the time of enrollment:

    • (NYHA) heart function classification is level III or IV;
    • Uncontrolled angina, congestive heart failure or myocardial infarction within 6 months before enrollment;
    • (LVEF) \<50% or lower limit of normal in echocardiogram (ECHO) or multi-gate detection scan (MUGA);
    • Average adjusted prolongation (male>450 ms, female>470 ms), QT interval corrected by Fridericia's formula (QTcF).
  14. The cumulative amount of previous exposure to anthracyclines has reached the following doses: doxorubicin or liposomal doxorubicin>500 mg/m2; epirubicin>900 mg/m2; mitoxantrone>120 mg/m2.
  15. Peripheral neuropathy ≥ grade 2 before entry (refer to NCI CTCAE 5.0).
  16. Uncontrollable electrolyte imbalances include hypokalemia, hypocalcemia or hypomagnesemia (refer to NCI CTCAE 5.0, ≥2 grade).
  17. Patients with active or C (HBsAg positive, with HBV DNA positive, and the continues to be higher than the , without other causes of ALT elevation; HCVAb positive with higher than the upper limit of normal).
  18. Test positive for or syphilis.
  19. Patients have used strong inhibitors (drugs that increase the AUC of specific CYP substrates ≥ 5 times, or CYP3A4 strong inducers with a less than 5 half-lives before the first dose of study drug.
  20. Patients underwent major surgery within 4 weeks and did not fully recover before the first dose of study drug.
  21. Chemotherapy, radiotherapy, immunotherapy and other anti-tumor treatments within 4 weeks before the first dose of study drug, within 2 weeks for Chinese medicine treatment with anti-tumor indications or local palliative radiotherapy for bone metastasis and pain relief; or within 5 half-lives for oral fluorouracil and small molecule targeted drugs.
  22. Patients have received other clinical trial drugs within 4 weeks before the first dose of study drug.
  23. Have previously received antibody drug conjugate targeting .
  24. Other serious or uncontrollable diseases or conditions that may affect the evaluation of the primary endpoint or the investigator believes that participation in this study may bring risks to the patient.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose-finding stage

    Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg,2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.

    Drug: DP303c treatment

  • Experimental
    Part 2: Cohort A

    Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.

    Drug: DP303c treatment(second-line of HER2-positive)

  • Experimental
    Part 2: Cohort B

    Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.

    Drug: DP303c treatment (third-line of HER2-positive)

  • Experimental
    Part 2: Cohort C

    Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.

    Drug: DP303c treatment(≥second-line of HER2 low expressing)

  • Experimental
    Part 2: Cohort D

    Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.

    Drug: DP303c + PD-1/PD-L1 treatment

Interventions

06

What researchers measure

Primary outcomes

  1. ORR(Objective Response Rate)

    The percentage of patients with a complete response (CR) or partial response (PR).

    Time frame: Up to 2.5 years

Secondary outcomes

  1. PFS(Progression Free Survival)

    The time from the first dose of study treatment to the date of documented disease progression, clinical progression, or death from any cause.

    Time frame: Up to 2.5 years

  2. OS(Overall Survival)

    The time from the first dose of study treatment until the date of death from any cause.

    Time frame: Up to 2.5 years

  3. DCR(Disease Control Rate)

    Number of subjects who achieved a best response of CR, PR, or SD during treatment.

    Time frame: Up to 2.5 years

  4. DOR(Duration of Response)

    The time from the first objective response (CR or PR) to documented PD, clinical progression, or death from any cause.

    Time frame: Up to 2.5 years

  5. AEs and SAEs

    Incidence of adverse events and serious adverse events.

    Time frame: Up to 2.5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All researchers can share the IPD from the EDC(the database to collecting the information of each participant ),including AEs,SAEs,ORR,PFS,OS.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: During the whole study.

Access criteria: All the researchers enrolled in this trial.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2021; primary completion for Aug 2024, 36 months later.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 36 months is close to that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Apr 1, 2021
StartEst.
Aug 2021
Primary completionEst.
Aug 2024
CompletionEst.
Dec 2024
Last update
Apr 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04826107
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Aug 2021 (estimated)
Primary completion
Aug 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 1, 2021

Study contacts

Xu JianMing, Ph.D
Contact
jmxu2003@163.com
010-66939843
Xu JianMing, Ph.D
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab envedotin

Start the discussion